No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Amicus Therapeutics, a biotechnology enterprise, is committed to the research, development, and commercialization of therapeutic solutions for rare genetic conditions. Its flagship commercial product, Galafold, is a precise, orally administered medication intended for adult patients with a verified diagnosis of Fabry disease who possess a treatable galactosidase alpha gene variant, as indicated by in vitro laboratory assays. The company's robust development pipeline features AT-GAA, an innovative therapeutic approach for Pompe disease, in addition to other enzyme replacement therapies targeting this same condition. Amicus is also conducting a Phase 1/2 clinical trial for CLN3, which is assessing the safety and effectiveness of a solitary intrathecal administration of its AT-GTX-502 gene therapy (an AAV serotype) in affected individuals. Furthermore, research efforts are underway for therapies related to CDKL5, an X-linked gene responsible for coding a protein crucial for regulating essential brain development proteins. Amicus Therapeutics maintains strategic collaboration and licensing agreements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. Established in 2002, the company's corporate headquarters are located in Philadelphia, Pennsylvania.
amicusrx.comNo one on the platform currently holds 0HF9.L.
No tracked institution reports a position in 0HF9.L as of their last filing.
No one on the platform has traded 0HF9.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -900.7% | — | — | — | ||
| Rev. Growth % | 20.0% | 19.4% | ||||
| Profit Margin % | -4.3% | -41.3% | -569.5% | |||
| Free Cash Flow Margin % | 4.7% | -28.2% | -446.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $754M | +19.6% | $0.36 | $0.34–$0.36 | — | 1 |
| 2027 | $896M | +18.9% | $0.64 | $0.62–$0.65 | — | 1 |
| 2028 | $1.1B | +22.2% | $0.91 | $0.88–$0.93 | — | 1 |
| 2029 | $1.3B | +19.3% | $1.36 | $1.32–$1.38 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-20 | $0.07 | $0.01 | -86.0% |
| 2025-11-04 | $0.04 | $0.06 | +44.5% |
| 2025-07-31 | $-0.12 | $-0.08 | +32.7% |
| 2025-05-01 | $-0.05 | $-0.07 | -29.1% |
| 2025-02-19 | $0.01 | $0.05 | +295.9% |
| 2024-11-06 | $0.00 | $-0.02 | -1971.2% |
| 2024-08-08 | $-0.05 | $-0.05 | +5.9% |
| 2024-05-09 | $-0.06 |
| $-0.16 |
| -148.3% |
| +0.44% |
| $1.3B |
| — |
| 0K1R.LViridian Therapeutics, Inc. | $21.90 | +1.44% | $2.0B | — |
| 0KCS.LOPKO Health, Inc. | $1.63 | +3.82% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry